S&P 500   4,082.93 (+0.07%)
DOW   34,445.36 (-0.42%)
QQQ   293.68 (+0.11%)
AAPL   148.54 (+0.34%)
MSFT   255.26 (+0.05%)
META   120.17 (+1.75%)
GOOGL   101.17 (+0.18%)
AMZN   95.56 (-1.02%)
TSLA   194.66 (-0.02%)
NVDA   171.79 (+1.51%)
NIO   12.09 (-5.40%)
BABA   86.14 (-1.62%)
AMD   77.26 (-0.48%)
T   19.17 (-0.57%)
MU   55.50 (-3.73%)
CGC   3.84 (+6.08%)
F   14.07 (+1.22%)
GE   85.35 (-0.72%)
DIS   98.37 (+0.51%)
AMC   8.70 (+20.33%)
PYPL   78.33 (-0.10%)
PFE   51.02 (+1.78%)
NFLX   318.26 (+4.17%)
S&P 500   4,082.93 (+0.07%)
DOW   34,445.36 (-0.42%)
QQQ   293.68 (+0.11%)
AAPL   148.54 (+0.34%)
MSFT   255.26 (+0.05%)
META   120.17 (+1.75%)
GOOGL   101.17 (+0.18%)
AMZN   95.56 (-1.02%)
TSLA   194.66 (-0.02%)
NVDA   171.79 (+1.51%)
NIO   12.09 (-5.40%)
BABA   86.14 (-1.62%)
AMD   77.26 (-0.48%)
T   19.17 (-0.57%)
MU   55.50 (-3.73%)
CGC   3.84 (+6.08%)
F   14.07 (+1.22%)
GE   85.35 (-0.72%)
DIS   98.37 (+0.51%)
AMC   8.70 (+20.33%)
PYPL   78.33 (-0.10%)
PFE   51.02 (+1.78%)
NFLX   318.26 (+4.17%)
S&P 500   4,082.93 (+0.07%)
DOW   34,445.36 (-0.42%)
QQQ   293.68 (+0.11%)
AAPL   148.54 (+0.34%)
MSFT   255.26 (+0.05%)
META   120.17 (+1.75%)
GOOGL   101.17 (+0.18%)
AMZN   95.56 (-1.02%)
TSLA   194.66 (-0.02%)
NVDA   171.79 (+1.51%)
NIO   12.09 (-5.40%)
BABA   86.14 (-1.62%)
AMD   77.26 (-0.48%)
T   19.17 (-0.57%)
MU   55.50 (-3.73%)
CGC   3.84 (+6.08%)
F   14.07 (+1.22%)
GE   85.35 (-0.72%)
DIS   98.37 (+0.51%)
AMC   8.70 (+20.33%)
PYPL   78.33 (-0.10%)
PFE   51.02 (+1.78%)
NFLX   318.26 (+4.17%)
S&P 500   4,082.93 (+0.07%)
DOW   34,445.36 (-0.42%)
QQQ   293.68 (+0.11%)
AAPL   148.54 (+0.34%)
MSFT   255.26 (+0.05%)
META   120.17 (+1.75%)
GOOGL   101.17 (+0.18%)
AMZN   95.56 (-1.02%)
TSLA   194.66 (-0.02%)
NVDA   171.79 (+1.51%)
NIO   12.09 (-5.40%)
BABA   86.14 (-1.62%)
AMD   77.26 (-0.48%)
T   19.17 (-0.57%)
MU   55.50 (-3.73%)
CGC   3.84 (+6.08%)
F   14.07 (+1.22%)
GE   85.35 (-0.72%)
DIS   98.37 (+0.51%)
AMC   8.70 (+20.33%)
PYPL   78.33 (-0.10%)
PFE   51.02 (+1.78%)
NFLX   318.26 (+4.17%)
NASDAQ:PRPH

ProPhase Labs - PRPH Stock Forecast, Price & News

$10.60
+0.23 (+2.22%)
(As of 12/1/2022 02:38 PM ET)
Add
Compare
Today's Range
$10.18
$10.60
50-Day Range
$9.63
$12.53
52-Week Range
$6.00
$15.25
Volume
953 shs
Average Volume
82,122 shs
Market Capitalization
$172.57 million
P/E Ratio
5.82
Dividend Yield
N/A
Price Target
$15.00

ProPhase Labs MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
44.1% Upside
$15.00 Price Target
Short Interest
Bearish
3.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of ProPhase Labs in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $1.09 to ($0.63) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

729th out of 1,047 stocks

Pharmaceutical Preparations Industry

358th out of 512 stocks

PRPH stock logo

About ProPhase Labs (NASDAQ:PRPH) Stock

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Receive PRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter.

PRPH Stock News Headlines

ProPhase Labs (NASDAQ:PRPH) Stock Rating Lowered by StockNews.com
ProPhase Labs, Inc. (PRPH) Q3 Earnings Miss Estimates
Are Investors Undervaluing Assertio (ASRT) Right Now?
ProPhase Labs Announces Collaboration with G42 Healthcare
ProPhase Labs to Present at The ThinkEquity Conference
5 Big Winners as Dollar Strengthens on Fed Rate Hike
PRPH ProPhase Labs, Inc.
Are Medical Stocks Lagging ProPhase Labs (PRPH) This Year?
See More Headlines
Receive PRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter.

PRPH Company Calendar

Last Earnings
11/12/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/29/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRPH
Employees
95
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+41.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$6.27 million
Pretax Margin
25.84%

Debt

Sales & Book Value

Annual Sales
$79.04 million
Cash Flow
$0.41 per share
Book Value
$4.17 per share

Miscellaneous

Free Float
10,988,000
Market Cap
$172.57 million
Optionable
Not Optionable
Beta
-0.27

Key Executives

  • Mr. Ted William Karkus (Age 63)
    Chairman & CEO
    Comp: $941.4k
  • Ms. Monica Brady (Age 45)
    Chief Accounting Officer
    Comp: $233.91k
  • Ms. Alice Lioi
    Exec. VP & Co-COO
  • Mr. Jason Karkus
    Exec. VP & Co-COO
  • Mr. Sergio Miralles
    Exec. VP & Chief Information Officer of ProPhase Diagnostics
  • Mr. Billy Joe White (Age 61)
    Consultant













PRPH Stock - Frequently Asked Questions

Should I buy or sell ProPhase Labs stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRPH, but not buy additional shares or sell existing shares.
View PRPH analyst ratings
or view top-rated stocks.

What is ProPhase Labs' stock price forecast for 2023?

2 analysts have issued 12-month target prices for ProPhase Labs' stock. Their PRPH share price forecasts range from $15.00 to $15.00. On average, they predict the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 45.2% from the stock's current price.
View analysts price targets for PRPH
or view top-rated stocks among Wall Street analysts.

How have PRPH shares performed in 2022?

ProPhase Labs' stock was trading at $7.17 at the beginning of 2022. Since then, PRPH stock has increased by 44.1% and is now trading at $10.33.
View the best growth stocks for 2022 here
.

Are investors shorting ProPhase Labs?

ProPhase Labs saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 425,800 shares, an increase of 16.2% from the October 31st total of 366,400 shares. Based on an average daily trading volume, of 93,900 shares, the days-to-cover ratio is currently 4.5 days. Currently, 3.4% of the company's shares are short sold.
View ProPhase Labs' Short Interest
.

When is ProPhase Labs' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our PRPH earnings forecast
.

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by $0.33. The firm had revenue of $9.47 million for the quarter, compared to analysts' expectations of $9.08 million. ProPhase Labs had a trailing twelve-month return on equity of 42.50% and a net margin of 21.58%. During the same quarter in the previous year, the business posted ($0.05) EPS.

How often does ProPhase Labs pay dividends? What is the dividend yield for ProPhase Labs?

ProPhase Labs announced a dividend on Friday, May 13th. Stockholders of record on Wednesday, May 25th will be paid a dividend of $0.30 per share on Friday, June 3rd. The ex-dividend date of this dividend is Tuesday, May 24th.
Read our dividend analysis for PRPH
.

What is Ted Karkus' approval rating as ProPhase Labs' CEO?

2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ProPhase Labs own?
What is ProPhase Labs' stock symbol?

ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."

Who are ProPhase Labs' major shareholders?

ProPhase Labs' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.58%), Renaissance Technologies LLC (2.35%), Avidian Wealth Solutions LLC (0.97%), BlackRock Inc. (0.81%), Perritt Capital Management Inc. (0.75%) and Marshall Wace LLP (0.53%). Insiders that own company stock include Jason Michael Barr, Louis Md Gleckel and Ted William Karkus.
View institutional ownership trends
.

How do I buy shares of ProPhase Labs?

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProPhase Labs' stock price today?

One share of PRPH stock can currently be purchased for approximately $10.33.

How much money does ProPhase Labs make?

ProPhase Labs (NASDAQ:PRPH) has a market capitalization of $168.17 million and generates $79.04 million in revenue each year. The company earns $6.27 million in net income (profit) each year or $1.82 on an earnings per share basis.

How can I contact ProPhase Labs?

ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The official website for the company is www.prophaselabs.com. The company can be reached via phone at (215) 345-0919, via email at ir@prophaselabs.com, or via fax at 215-345-5920.

This page (NASDAQ:PRPH) was last updated on 12/1/2022 by MarketBeat.com Staff